Head-to-head evidence
BAT1706 vs Bevacizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
BAT1706 · Avzivi
Marketed by Bio-Thera Solutions
NCT03329911 · Phase 3 · completed
The trial was randomized, double-blind, and actively controlled, with 651 participants, and used a clinical tumor-response endpoint assessed by RECIST 1.1. However, the week-18 primary endpoint comparison is unclear because only response counts are posted and no statistical analysis is reported.
Bevacizumab
Marketed by Roche
NCT00806923 · Phase 3 · completed
This is a large, randomized, placebo-controlled trial with a clinical primary endpoint (progression-free survival). Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: October 2026 · NCT06447662 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1706's landscape · Bevacizumab's landscape